Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
Small cell lung cancer
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Would they significantly interfere with each other? Thank you.
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240 mg versus 960 mg dose of sotorasib?
What are your top takeaways in thoracic cancers from ESMO 2025?
Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?